Product Information
PRAMIPEXOLE ER 0.75 MG TABLET is a generic product labeled by Vitruvias Therapeutics Inc., priced at $0.7178 per EA under NDC 69680014630. Its NADAC has been published 216 times since Apr 20, 2022.
FDA first approved this application on Jun 11, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.75 mg/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680014630
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PRAMIPEXOLE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212797FDA Approved
6/11/2021
TE Code
AB
On Market Since
8/27/2021
Pharmacological Classes
Price Statistics
The NADAC for PRAMIPEXOLE ER 0.75 MG TABLET has been published 216 times since Apr 20, 2022, and over the history we have for it it has declined 90.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7178 per EA |
|---|---|
| All-time high | $7.8084 (Dec 14, 2022) |
| All-time low | $0.7178 (Sep 23, 2026) |
| 52-week high | $1.4031 |
| 52-week low | $0.7178 |
| Median price | $2.2295 |
| Average price | $2.8781 |
| Largest weekly change | -71.4% (Dec 21, 2022) |
| Weeks tracked | 216 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pramipexole Dihydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRAMIPEXOLE ER 0.75 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PRAMIPEXOLE ER 0.75 MG TABLET, manufactured by Vitruvias Therapeutics Inc., is $0.7178 per EA (NDC 69680014630), effective Sep 30, 2026.
How has the price of PRAMIPEXOLE ER 0.75 MG TABLET changed over time?
Over the history we have for it, the NADAC for PRAMIPEXOLE ER 0.75 MG TABLET has declined 90.8%. It has been tracked across 216 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for PRAMIPEXOLE ER 0.75 MG TABLET?
Since Apr 20, 2022, the NADAC for PRAMIPEXOLE ER 0.75 MG TABLET has ranged from a low of $0.7178 (Sep 23, 2026) to a high of $7.8084 (Dec 14, 2022), with a median of $2.2295 per EA.
Are there cheaper alternatives to PRAMIPEXOLE ER 0.75 MG TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PRAMIPEXOLE 0.75 MG TABLET, is $0.0721 per EA — about 90% below PRAMIPEXOLE ER 0.75 MG TABLET.
Who manufactures PRAMIPEXOLE ER 0.75 MG TABLET?
PRAMIPEXOLE ER 0.75 MG TABLET (NDC 69680014630) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.